Medication math isn’t just numbers—it’s a frontline defense against errors that can harm patients. From IV drip rates to pediatric safe dose ranges, mastering calculations builds confidence and ...

Drug development programs for neurological and psychiatric diseases have a high failure rate in both phase II and phase III [1, 2]. Reasons include the lack of safety and efficacy in clinical stages ...

Parkinson’s disease (PD) affects 1–2% of the population over 65 years, and is one of the fastest growing neurological disorders worldwide 1,2. Current treatments for PD provide partial and temporary ...